Primary human mesothelioma cells express class II MHC, ICAM‐1 and B7–2 and can present recall antigens to autologous blood lymphocytes

Mesothelioma cells (MMc) are considered to be weakly immunogenic and the experimental approaches attempting to induce an immune response against these cells have been disappointing. Our aim was to investigate whether MMc possess the surface accessory molecules involved in antigen presentation and whether these cells are capable of presenting recall antigens to autologous blood lymphocytes. Four primary MMc cultures were generated from malignant effusions and examined to assess whether the accessory molecules required for antigen presentation were present on their surfaces. Intercellular adhesion molecule‐1 (ICAM‐1; CD54); class I and class II major histocompatibility complex‐DR (MHCI and MHCII‐DR); B7–1 (CD80.3); and B7–2 (CD86) expression by MMc was studied by immunocytochemical and/or FACScan analysis. MMc were pulsed with purified protein derivative (PPD), Tetanus toxoid (TT) and Candida albicans (CA) bodies, and incubated with autologous lymphocytes. Lymphocyte proliferation was estimated by radionucleotide incorporation. Phenotypic analysis showed the presence of MHCII‐DR, ICAM‐1 and B7–2 on primary MMc cultures, whereas the phenotypic evaluation of 2 established MMc lines did not show the presence of the B7–1 and B7–2 molecules. In addition, MHCII‐DR was detectable only after interferon gamma (IFN‐γ) stimulation. Primary MMc cultures acquired the capability to induce lymphocyte proliferation after pulse with the recall antigens. To achieve characterization of these lymphocytes, we generated a PPD‐specific CD4+ T‐cell clone. PPD‐pulsed MMc were shown to specifically induce T‐cell clone proliferation through a MHCII‐DR‐mediated process. We conclude that primary MMc possess the surface molecules required for antigen presentation and can present recall antigens to CD4+ lymphocytes. Int. J. Cancer 78:740–749, 1998. © 1998 Wiley‐Liss, Inc.

[1]  N. Hayashi,et al.  Expression of costimulatory molecules B7‐1 (CD80) and B7‐2 (CD86) on human hepatocellular carcinoma , 1997, Hepatology.

[2]  D. Fitzpatrick,et al.  Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. , 1996, Cancer research.

[3]  T. H. van der Kwast,et al.  EXPRESSION OF ICAM‐1 AND VCAM‐1 IN HUMAN MALIGNANT MESOTHELIOMA , 1996, The Journal of pathology.

[4]  D. Fitzpatrick,et al.  Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma. , 1996, Cancer letters.

[5]  D. Fitzpatrick,et al.  MOLECULAR PATHOBIOLOGY AND IMMUNOLOGY OF MALIGNANT MESOTHELIOMA , 1996, The Journal of pathology.

[6]  N. Vogelzang,et al.  Chemotherapy in malignant pleural mesothelioma. A review. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Izbicki,et al.  Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells. , 1996, European journal of cancer.

[8]  C. Smith,et al.  Differential expression and release of CD54 induced by cytokines , 1995, Hepatology.

[9]  R. Gusmano,et al.  Antigen‐presenting function of human peritoneum mesothelial cells , 1995, Clinical and experimental immunology.

[10]  C. Leong,et al.  Biological and immunological aspects of malignant mesothelioma. , 1995, The European respiratory journal.

[11]  J. Zeuthen,et al.  A Human Melanoma Cell Line, Recognized by Both HLA Class I and Class II Restricted T Cells, is Capable of Initiating both Primary and Secondary Immune Responses , 1995, Scandinavian journal of immunology.

[12]  W. J. Matthews,et al.  Characteristics of nine newly derived mesothelioma cell lines. , 1995, The Annals of thoracic surgery.

[13]  J. Peto,et al.  Continuing increase in mesothelioma mortality in Britain , 1995, The Lancet.

[14]  J. Gribben,et al.  Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. , 1994, Blood.

[15]  B. Robinson,et al.  Generation of an antitumour immune response to a murine mesothelioma cell line by the transfection of allogeneic mhc genes , 1994, International journal of cancer.

[16]  J. Gribben,et al.  In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. , 1994, Blood.

[17]  D. Fitzpatrick,et al.  Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. , 1994, Growth factors.

[18]  L. Mutti,et al.  Expression of intercellular adhesion molecule-1 (ICAM-1) by reactive mesothelial cells in pleural effusions. , 1993, Pathologica.

[19]  N. Mavaddat,et al.  An analysis of the relationship between γδ T cell receptor V gene usage and non‐major histocompatibility complex‐restricted cytotoxicity , 1993 .

[20]  T. Whiteside,et al.  T cell recognition of human tumors: implications for molecular immunotherapy of cancer. , 1993, Clinical immunology and immunopathology.

[21]  P. Astoul,et al.  Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. , 1993, Chest.

[22]  B. Robinson,et al.  HLA antigen expression and malignant mesothelioma. , 1991, American journal of respiratory cell and molecular biology.

[23]  V. Rusch,et al.  The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. , 1991, The Journal of thoracic and cardiovascular surgery.

[24]  F. Celada,et al.  Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies , 1991, The Journal of experimental medicine.

[25]  T. Ottenhoff,et al.  Specific killing of cytotoxic T cells and antigen-presenting cells by CD4+ cytotoxic T cell clones. A novel potentially immunoregulatory T-T cell interaction in man , 1990, The Journal of experimental medicine.

[26]  D. Ball,et al.  The Treatment of Malignant Mesothelioma of the Pleura: Review of a 5‐Year Experience, With Special Reference to Radiotherapy , 1990, American journal of clinical oncology.

[27]  R. Bowman,et al.  Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells. , 1989, The American review of respiratory disease.

[28]  T. Boon,et al.  Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis , 1983, The Journal of experimental medicine.

[29]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .

[30]  L. Morasca Effect of triazolium derivatives on the growth of tissue cultured cells. , 1965, European journal of cancer.